VentiRx Pharmaceuticals

Advancing healthcare innovations with targeted therapies for cancer, respiratory, and autoimmune diseases.

Founded 2006 Series B Total: $104.50M Biotechnology, Health Care +1

VentiRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, respiratory, and autoimmune diseases. The company's product pipeline includes VTX-2337, a small molecule TLR8 agonist designed to stimulate myeloid dendritic cells and monocytes, enhancing natural killer cell responses to treat solid tumors, ovarian and breast cancers, and NHL and SCHN. In addition, VTX-1463 is a standalone agent for seasonal and perennial allergies, and the company also works on TLR8 antagonists aiming to treat autoimmune diseases as well as multiple compounds treated as vaccine adjuvants. The strategic agreement/collaboration with Celgene Corporation further emphasizes the company's potential in advancing healthcare innovations. VentiRx Pharmaceuticals, founded in 2006, is headquartered in Seattle, Washington, with operations in San Diego. The company raised a $50.60M Series B investment on 23 September 2014, with key investors including Arch Venture Partners, Domain Associates, Frazier Healthcare Partners, Celgene, and MedImmune Ventures.

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	$50.60M	5	Arch Venture Partners, Domain Associates +3	23 Sep 2014
Series A	$25.00M	4	Arch Venture Partners, Domain Associates +2	13 Jan 2010
Series A	$26.60M	1	Frazier Healthcare Partners	06 Mar 2007
Seed Round	$2.30M	-		01 Jan 2006

Funding Stage

Amount

Investors

Lead Investors

Date

Series B

$50.60M

Arch Venture Partners, Domain Associates +3

23 Sep 2014

Series A

$25.00M

Arch Venture Partners, Domain Associates +2

13 Jan 2010

Series A

$26.60M

Frazier Healthcare Partners

06 Mar 2007

Seed Round

$2.30M

01 Jan 2006

FAQ About VentiRx Pharmaceuticals

Advancing healthcare innovations with targeted therapies for cancer, respiratory, and autoimmune diseases.

VentiRx Pharmaceuticals was founded in 2006.

VentiRx Pharmaceuticals operates in Biotechnology, Health Care and Health and Wellness. Its work centres on biopharmaceutical, clinical-stage, cancer treatment and respiratory diseases.

VentiRx Pharmaceuticals has completed 4 funding rounds, raising a total of $104.50M. The latest funding stage is Series B.

Top alternatives and competitors to VentiRx Pharmaceuticals include Synta Pharmaceuticals, GlobeImmune, Inc., Cascadian Therapeutics, Inc., TargeGen, Inc., Biond Biologics Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

VentiRx Pharmaceuticals and Synta Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About VentiRx Pharmaceuticals

Funding Rounds & Investors (4)

VentiRx Pharmaceuticals Alternatives & Competitors

FAQ About VentiRx Pharmaceuticals